Combretastatin A-1
Names | |
---|---|
Preferred IUPAC name 3-Methoxy-6-[(E)-2-(3,4,5-trimethoxyphenyl)ethen-1-yl]benzene-1,2-diol | |
Other names Combretastatin A1; OXi4500 | |
Identifiers | |
CAS Number |
|
3D model (JSmol) |
|
ChEMBL |
|
ChemSpider |
|
PubChem CID |
|
UNII |
|
InChI
| |
| |
Properties | |
Chemical formula | C18H20O6 |
Molar mass | 332.352 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). N verify (what is YN ?) Infobox references |
Chemical compound
Combretastatin A-1 is a combretastatin and a stilbenoid. It can be found in Combretum afrum, the Eastern Cape South African Bushwillow tree.[1]
Biological effects in mammals
It is an antiangiogenic agent acting by destabilizing tubulin, which induces cell apoptosis of proliferating endothelial cells.[1]
Derivatives as drugs
Currently designated an orphan drug by the FDA, combretastatin A1 diphosphate (OXi4503 or CA1P) is in Phase I clinical trials for relapsed and refractory acute myeloid leukemia and myelodysplastic syndrome.[2]
References
- ^ a b Pettit, G. R.; Singh, S. B.; Niven, M. L.; Hamel, E.; Schmidt, J. M. (1987). "Isolation, Structure, and Synthesis of Combretastatins A-1 and B-1, Potent New Inhibitors of Microtubule Assembly, Derived from Combretum caffrum". Journal of Natural Products. 50 (1): 119–131. doi:10.1021/np50049a016. PMID 3598594.
- ^ "A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS)". 7 August 2017.
- v
- t
- e
Hydroxystilbenes and their glycosides (monomeric forms)
| |
Combretastatins |
|
---|
| |||||
|
This article about an aromatic compound is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e